Kihealth Raises $5M in Oversubscribed Seed Round to Launch First-of-Its-Kind Diabetes Diagnostic

▤ Summary

Kihealth raised $5 million in an oversubscribed seed round to support the commercial rollout of its new diabetes diagnostic. The company says the test measures biomarkers of beta cell apoptosis from a simple blood draw and aims to detect disease earlier than current approaches. Kihealth positions the product as a way to improve patient stratification, trial enrollment, and treatment monitoring in diabetes prevention and obesity care. The company also says the technology opens a large diagnostics market with few direct competitors. The funding should help Kihealth scale its go-to-market efforts and expand its pipeline of minimally invasive diagnostics.

$ Funding

▦ Linked Companies